rostate cancer is the most commonly diagnosed cancer aft er skin cancer and the second leading cause of cancer death for American men, behind only lung cancer.
Several factors have been suggested to infl uence time-to-treatment in cancer patients, including socioeconomic status and other demographic characteristics. [12] [13] [14] [15] In breast cancer, for instance, studies have shown that time-to-treatment may be linked to socioeconomic status as well as race. The same studies suggested that delays of greater than three months aft er an initial diagnosis may decrease breast cancer survival by 12%. [13] [14] [15] [16] Some studies found that men with prostate cancer experience longer wait time for diagnosis and treatment than those observed for other cancers. [17] [18] [19] Studies in both the urologic and medical literature have paid increasing attention to the question of overdiagnosis in prostate cancer. As evidence, a study reported overdiagnosis rates of 15% among White men and 37% among Black men. 20 The association between wait time and prognosis of prostate cancer is inconclusive. [21] [22] [23] [24] [25] [26] Even though we recognize the current literature's debate on whether or not prostate cancer has been over-treated, the intent of this project was not to make a clinical judgment about this matter. This study intended to investigate factors contributing to time-to-treatment and examine whether there was a diff erence in wait time or treatment rate between African American and Caucasian men in Florida.
Methods
Population studied. Caucasian and African American men 40 years of age or older diagnosed with prostate cancer between Oct. 2001 and Dec. 2007 in Florida. Other races were excluded due to small numbers in the dataset.
Data sources. The study used data from three sources. First, prostate cancer incidence data between Oct. 2001-Dec. 2007 were obtained from the Florida Cancer Data System (FCDS) that is managed by State of Florida Department of Health and housed at the University of Miami through a contract. The FCDS is the largest population-based, cancer incidence registry in the nation. 27 It contains information on patient demographic characteristics, residence, prostate tumor characteristics, and other information such as tobacco use and primary payer of health insurance.
Second, comorbidity data were obtained from the Florida Agency for Health Care and Administration (AHCA). The AHCA maintains two databases (Hospital Patient Discharge Data and Ambulatory Outpatient Data) on all patient encounters within hospitals and freestanding ambulatory surgical and radiation therapy centers in Florida. Comorbidity was computed following the Elixhauser Index method 28 based on diagnoses information from AHCA. The study used a total of 45 conditions, including 29 from the Elixhauser Index plus 16 new additional conditions based on clinical characteristics of the study population.
Third, data on demographic and area-level socioeconomic characteristics were extracted at the census tract level from the U.S. Census Bureau public use fi les (Census 2000, Summary File-3) for the State of Florida. Data obtained from the three sources were merged into a single dataset for analyses.
Statistical analysis. Time from diagnosis to initial treatment of prostate cancer was calculated. Patients who did not receive any treatment by last recorded follow up, including watchful waiting cases, were censored at time of last follow-up. Descriptive statistics were used to summarize sample characteristics, t-tests and chi-square tests were used for bivariate racial comparisons in Table 1 ; Kaplan-Meier estimator was applied to generate estimated survival probability curves in fi gures (probability waiting time is beyond a given time in our case). Wei, Lin and Weissfeld (WLW) survival model 29 was utilized to examine eff ects of exploratory variables on time-to-treatment while accounting for possible correlation of patients from same census tract. This model choice was supported by the ratio of the robust standard error estimate relative to the model-based estimate that ranged from 0.6 to 1.5, where departure from one indicates improvement while accounting for correlation. Hazard ratios and p-values were calculated. The event of interest in this study was receiving initial treatment instead of death as frequently seen in publications involving time-to-event analysis. Therefore "hazard" in this study is interpreted as treatment rate instead of death rate, and a higher treatment rate corresponds to a shorter waiting time before treatment. Survival probability at any time t in fi gures is interpreted as the chance that waiting time before initial treatment is longer than time t i.e. chance that patient is still waiting at time t. Statistical analyses were carried out using SAS/STAT® soft ware, Version 9.3 of the SAS System for Windows.
Results
Population characteristics. Characteristics of the study population are summarized in Table 1 . A total of 11,284 men diagnosed with prostate cancer in Florida during Oct. 2001-Dec. 2007 were included in the study, among whom 12.61% were diagnosed at latestage. Patient age in the study ranged from 40 to 99 at diagnosis, with a median diagnosis age of 66 years. The average age at diagnosis was 66.36 years. About 87.57% of the study population was Caucasian and 12.43% was African American. Most patients were married (79.08%). The majority of the sample had public health insurance (56.67%). Public health insurance includes Medicare, Medicaid, Department of Defense (Tricare), military personnel (military), veteran aff airs, or Indian/Public Health Service. Since the study only included three months of 2001 data, proportion of 2001 cases was lower than those of later years. Compared with Caucasian men, African American men were diagnosed at a younger age on average, had a lower percentage of patients treated with radiation only, a lower proportion of married patients, a higher uninsured rate, a lower share of patients with well-moderately diff erentiated tumor, and a larger fraction of late stage diagnosis.
The observation period ranged from 0 days to 2,408 days (approximately six and a half years). The median time-to-treatment was 47 days, indicating 50% of patients received initial treatment within 47 days aft er diagnosis. Curves in Figures 1 and 2 dramatically drop down to approximately 90% at around diagnosis time, indicating approximately 10% of patients sought initial treatment shortly aft er diagnosis. Overall racial comparison of waiting probability for time-to-treatment in Figure 1 and racial comparisons by stage in Figure 2 both indicate that in general African American men had a higher chance to wait a longer time before receiving initial treatment.
Multilevel analysis. The analysis was performed for early-stage and late-stage patients separately. The results are shown in Tables 2 and 3 . The comorbidity conditions that were not signifi cant in the analysis were listed separately in Appendix 1 and 2. Among patients diagnosed with early prostate cancer, higher rate of treatment was associated with being diagnosed at for-profi t facilities and/or hospitals. Wait time increased for African American patients and those who lived in areas with higher percentages of African American population. These eff ects did not change over time. For patients diagnosed with early-stage prostate cancer, presence of diabetes without chronic complications was associated with shorter wait time. Two comorbidity conditions were associated with longer waiting time: psychoses, and benign neoplasm and in-situ cancer. Similar to the association observed among early-stage cases, late-stage patients living in area with higher percentage of African American population had longer waiting time and this eff ect did not change over time. More comorbidity conditions became signifi cant factors of shorter waiting time for late-stage patients. Specifi cally, treatment rate was higher among men with liver disease, solid tumor without metastasis, rheumatoid arthritis/collagen vascular disease, defi ciency anemias, drug abuse, and genitourinary system disease.
Patients diagnosed in more recent years had lower treatment rate than those diagnosed in early years. This pattern was observed for both early and late stage.
Discussion
Our study diff ers from other studies investigating time-to-treatment among cancer patients in two major ways: 1) it utilized both the state cancer registry data and patient's diagnosis of other conditions to present a much more complete sickness profi le of men with prostate cancer, and 2) early and late-stage prostate cancer cases were analyzed separately.
Prostate cancer typically tends to grow slowly, which can explain why men diagnosed with late-stage prostate cancer wait less to receive treatment than those diagnosed at early-stage. Signifi cantly shorter wait times were also observed for older patients, which is consistent with a study by Johnston and colleagues 30 and may be partly due to easier access to health care. Indeed, in the U.S. the elderly are more likely to hold health insurance and, thus interact with health care provider more frequently than younger men. On the other hand, a population-based study in Canada with universal health coverage reported no diff erence in treatment wait time. 31 Other studies have also suggested that due to rising prevalence of coexisting diseases with age and certain physiologic changes in the elderly, which may reduce their capacity to tolerate therapeutic complications, elderly patients were less likely to undergo treatments for prostate cancer. 32, 33 Another fi nding of our study is that characteristics of facility where prostate cancer was diagnosed have some impact on time-to-treatment. Men who were diagnosed in hospital settings with early-stage prostate cancer had a shorter wait time compared with those in ambulatory settings. For late-stage patients, treatment rates were comparable among diagnosis facilities. For early-stage disease, men who were diagnosed at for-profi t facilities were more likely to wait longer. However, the reasons for this It is unclear whether longer time-to-treatment is related to treatment capacity issues, or provider and patient decisions or preferences. The presence of some comorbidity reduced wait time to prostate cancer treatment. Men with other solid tumors without metastasis received treatment sooner regardless of prostate cancer stage. For men diagnosed with early-stage prostate cancer, having diabetes without chronic complications or other metastatic cancers, was associated with shorter wait time. Since these men are already in the health care system being treated for these co-existing conditions, they should be more likely to be treated early for prostate cancer. It is hard to explain why time-to-treatment of early-stage prostate cancer was lengthened when men had diabetes with other chronic complications and/ or other circulatory diseases. Among men with late-stage prostate cancer, wait time was shorter for those with conditions including but not limited to liver disease, lym- 34, 35 so it is may be necessary for these treatments to be coordinated.
Although our study did not reveal racial diff erences in time-to-treatment at the individual level, a contextual factor was found to aff ect treatment rate signifi cantly: the rate was lower in areas with high percentages of African American for analyses of both early-stage and late-stage patients, independent of age at diagnosis, health insurance, and the other factors. In other words, men who resided in predominantly African neighborhoods waited longer to have their prostate cancer treated than did those who lived in less African American-concentrated areas. Such a disparity may be explained in that predominantly African American neighborhoods have poorer health care facilities with less technology and fewer medical specialists, than do Caucasian neighborhoods. 36, 37 African American men have been found to be less likely than Caucasians to receive defi nitive treatment aft er being diagnosed with prostate cancer. 38 Since the value of treating prostate cancer has been questioned, and concrete evidence of benefi t from defi nitive treatment is lacking, it is not clear whether the disproportionate receipt of defi nitive treatment we observed for African Americans represents inappropriate care. Certain studies have contended that the preferences of African American men may diff er from Caucasians or that African American men may weigh the risks of defi nitive treatment diff erently. 38 Another view has been expressed that African American men are off ered optimal treatment less frequently than their Caucasian counterparts. 8 These are certainly issues worthy of investigation in future studies.
The current study has a number of limitations. First, only cases diagnosed from 2001 through 2007 were analyzed. As a result, the observations made in this analysis may not necessarily refl ect the most current trends. Second, census-tract socioeconomic data was used due to lack of individual-level information on socio-economic status which would have provided more accurate information for the analyses. Third, we have no data on treatment decision making to determine whether the wait time is related to physician/patient decision making, or patient preferences. Fourth, cancer registry data are subject to some limitations. Registry data lack information about events leading up to screening. Follow-up information are oft en limited to vital status, and there are no detailed information on side eff ects of treatment or treatment compliance. They off er very little information about recurrence of disease.
Despite these limitations, the study was able to maximize the utility of currently available information by linking three data sources and presented a comprehensive picture of patient outcomes. Specifi cally, patient comorbidity was taken into consideration, which is highly relevant to examining treatment rate among men diagnosed with prostate cancer.
Individual-level factors, such as comorbid conditions and sociodemographic characteristics should be considered in prostate cancer treatment. The fi ndings of this study have implications for clinical practice in prostate cancer. They show a diff erence in the time-to-treatment and also highlight the need for further study to understand treatment decision making for this disease. Further research is needed, especially in the midst of the ongoing debate about possible overdiagnosis and overtreatment of prostate cancer, to investigate the association between time-to-treatment and prostate cancer-specifi c patient outcomes such as survival and quality of life. 
Appendix 1. NONSIGNIFICANT COMORBIDITIES INCLUDED IN THE MULTIVARIATE ANALYSIS FOR EARLYSTAGE CASES

